TeamDrive
RUS

Domain Associates

www.domainvc.com

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.7 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.

Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics.  The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 260 life-sciences companies.  The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

www.dri.com.ru

Domain Russia Investments (DRI) is a company formed by U.S.-based life sciences venture capital firm Domain Associates to help foster innovation in the Russian health sciences sector. DRI plays a crucial role in Domain’s unique strategic collaboration with Rusnano. The collaboration focuses on co-investment into leading US life sciences companies and the eventual production of their innovative healthcare products for the Russian and CIS market.

Media Center

  • 20 July 2018

    Russian drugs with precise delivery system may become available in five years

    A system of intracellular drug delivery was developed at the Institute of Theoretical and Experimental Biophysics (ITEB) of The Russian Academy of Sciences (RAS). This principle is expected to be used to obtain highly effective anti-inflammatory drugs.

  • 19 July 2018

    China will bring down prices for cancer drugs

    China’s state medical insurance administration will start a new round of negotiations with pharmaceutical companies to add more cancer drugs to the insurance list.

  • 18 July 2018

    Russia and Bulgaria signed cooperation agreement

    Last week, on July 10, 2018, in Sofia Vladislav Shestakov – Director of the State Institute of Drugs and Good Practices, Deputy Head of the State GMP Inspectorate met with Professor Assena Stoimenova, Executive Director of the Bulgarian Drug Agency (Medicines Agency of the Bulgarian Health Ministry).

  • 18 July 2018

    EMA Relocation Countdown: Some Industry Viewpoints

    July 1, 2018 marked the start of the six-month countdown to the European Medicines Agency (EMA) relocation of its operations to Amsterdam. Worryingly, there remains little guidance or clarity from the EMA as to the implications of the move, and Brexit, on the pharma industry.

Read more